the CAR T
In a single infusion, YESCARTA can help you achieve complete and lasting remission
In a clinical study, YESCARTA was shown to help the majority of patients with large B-cell lymphoma who had experienced other treatment failures:
seeing a disappearance of all signs of cancer. This does not always mean the cancer has been cured
experiencing a decrease in the amount of cancer within the body
Patients were followed for a minimum of ~9 months after receiving YESCARTA to gather these results. Most of the patients who achieved remission are still in remission a year after treatment.
REMISSION IS POSSIBLE IN AS LITTLE AS
1 MONTH AFTER TREATMENT
In the YESCARTA clinical study, half of patients with large B-cell lymphoma achieved remission in as little as 1 month (range 0.8–6.2 months).
AT A 4-YEAR FOLLOW UP, NEARLY HALF OF PATIENTS TREATED WITH YESCARTA WERE STILL LIVING
The YESCARTA clinical study also evaluated how long patients would live after receiving treatment.
At the 4‑year follow-up, 44% of patients treated with YESCARTA were still alive. Not all of these
patients stayed in remission.
HOW YESCARTA WORKS
It starts with your own T cells
Your immune system has different types of white blood cells, all working together to keep you healthy. One type of white blood cell, called the T cell, has the very important job of finding and destroying things that can harm your body, like infection or cancer. In some cases, however, your T cells aren't able to recognize cancer cells.
YESCARTA helps your T cells do the job they were meant to do
The YESCARTA treatment process takes your own T cells and modifies them with a special connector called a chimeric antigen receptor, or CAR. With just one YESCARTA infusion, millions of CAR T cells are put into your body, giving it a better ability to recognize and destroy cancer cells.